Program Information t DTx, we are determined to solve one of the biggest challenges limiting the development of genetic medicines. Anchored by our expertise in RNA therapeutics and our proprietary FALCON??? platform, we???ve developed a unique pipeline of novel therapeutic candidates to help patients with ocular, neuromuscular and CNS diseases.